Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Combining MRD assays with functional imaging in multiple myeloma

Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly discusses the value of combining measurable residual disease (MRD) assays with functional imaging in patients with multiple myeloma to analyze outcomes after therapy. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.